Homburger advises Eli Lilly on the acquisition of LimmaTech Biologics

On May 26, 2026, Eli Lilly and Company (NYSE: LLY) announced the acquisition of LimmaTech Biologics AG for up to USD 780 m in cash, inclusive of an upfront payment and additional potential payments based upon the achievement of certain clinical and regulatory milestones. LimmaTech Biologics is developing vaccines against bacterial pathogens for which rising antimicrobial resistance is steadily closing therapeutic options.

The Homburger team advising Eli Lilly includes Anna Peter, Bianca Nedwed, Daniel Kuhn, Jana Waldvogel and Ivo Graf (all Corporate / M&A), Joel Fink (IP / IT), Jeremy Reichlin and Giulia Menegon (both Employment and Executive Compensation) as well as Stefan Oesterhelt and Juliette Buob (both Tax).